BIOGEN INC. - COMMON S

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

26 1 2023 18:30:00 提供 Nasdaq GlobeNewswire

Biogen Names Priya Singhal as Executive Vice President, Head of Development

05 1 2023 07:30:00 提供 Nasdaq GlobeNewswire

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

04 1 2023 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

19 12 2022 07:30:00 提供 Nasdaq GlobeNewswire

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

09 12 2022 07:30:00 提供 Nasdaq GlobeNewswire

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

05 12 2022 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Names Christopher Viehbacher President and Chief Executive Officer

10 11 2022 07:30:01 提供 Nasdaq GlobeNewswire

Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS

26 10 2022 06:05:00 提供 Nasdaq GlobeNewswire

New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS

26 10 2022 06:02:00 提供 Nasdaq GlobeNewswire

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

17 10 2022 07:30:10 提供 Nasdaq GlobeNewswire

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

30 9 2022 07:00:00 提供 Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS

21 9 2022 17:15:12 提供 Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus

07 9 2022 17:45:26 提供 Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

28 7 2022 07:30:00 提供 Nasdaq GlobeNewswire

FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

26 7 2022 07:30:02 提供 Nasdaq GlobeNewswire

European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

21 6 2022 06:37:05 提供 Nasdaq GlobeNewswire

New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)

15 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities

14 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

06 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)

03 6 2022 08:00:01 提供 Nasdaq GlobeNewswire